RPRXW Profile
Repros Therapeutics Inc. (RPRXW) was a pharmaceutical company that focused on the development of treatments for male and female reproductive disorders. However, it's important to note that Repros Therapeutics Inc. is no longer an active publicly traded company.
The company underwent a merger with Allergan plc in 2018, and the combined entity now trades under the ticker symbol AGN.
Prior to the merger, Repros Therapeutics Inc. had developed a number of products for the treatment of male and female reproductive disorders, including oral drugs and injectable treatments. The company's lead product, enclomiphene, was being developed for the treatment of secondary hypogonadism in men.
Overall, while Repros Therapeutics Inc. is no longer an active publicly traded company, its legacy can be seen in the continued development of its products by its successor, Allergan plc.
|
